Mounjaro Pill UK: Is Foundayo the New Mounjaro Tablet?

Is Foundayo the new Mounjaro pill?#

If you've been searching for a "Mounjaro pill" or "oral Mounjaro" — or you've heard that Eli Lilly has launched an oral version of Mounjaro in the UK — you're not alone in being confused. Here's the short answer: Foundayo is not a Mounjaro pill, and it is not oral tirzepatide.

Mounjaro is tirzepatide. Foundayo is orforglipron — a completely different drug molecule. Both are made by Eli Lilly, which is almost certainly where the confusion comes from. Eli Lilly has developed two separate oral weight-loss medications: Foundayo (orforglipron), which has just been approved in the UK, and a separate oral tirzepatide — the true Mounjaro tablet — that is still in clinical development and has not yet been approved anywhere in the world. So when people search for a "Mounjaro pill UK" or "tirzepatide pill", they are often thinking of that future oral tirzepatide, not Foundayo.

Foundayo is also sometimes confused with the Wegovy pill (oral semaglutide), which is another oral GLP-1 tablet — but from a different manufacturer (Novo Nordisk) and containing a different active ingredient.

To put it plainly:

• Mounjaro = tirzepatide injection (Eli Lilly)
• Foundayo = orforglipron tablet (Eli Lilly) — MHRA-approved August 2026
• Oral tirzepatide = the true Mounjaro pill / oral Mounjaro, still in development and not yet approved anywhere
• Wegovy pill = oral semaglutide tablet (Novo Nordisk)

With that cleared up, here's what the MHRA's approval of Foundayo actually means.

Foundayo has been approved by the MHRA — here's what that covers#

The MHRA approved Foundayo (orforglipron) on 10th August 2026, making the UK the first country in Europe to license it. It's a once-daily weight-loss tablet, and the headline feature is that you can take it whenever suits you, with or without food, without any water restrictions.

That might sound like a small detail, but if you've looked at the Wegovy pill, you'll know it has to be taken first thing in the morning, on an empty stomach, with no more than a small sip of water, followed by a 30-minute wait before eating or drinking anything else. Foundayo drops all of that.

The MHRA has licensed Foundayo for adults with a BMI of 30 or above, or a BMI of 27 to 30 alongside a weight-related condition such as high blood pressure or type 2 diabetes. It's meant to be used alongside a reduced-calorie diet and increased physical activity, not instead of them. Unlike the Wegovy pill, it's also licensed specifically for adults with type 2 diabetes whose blood sugar isn't well controlled, which broadens who it might suit.

It isn't available on the NHS, and it isn't on general sale yet either. New medications typically take a few weeks to reach pharmacies after approval, and Eli Lilly (the manufacturer) hasn't confirmed a UK launch date or price.

How well Foundayo actually works#

In the ATTAIN-1 trial, which underpins this approval, adults on the highest tested dose lost an average of 11.2% of their body weight over 72 weeks, compared with 2.1% on placebo. That's the figure calculated across everyone who enrolled, including those who didn't complete the full 72 weeks. You'll sometimes see 12.4% quoted instead, which only counts people who stayed on treatment to the end. We think the more conservative figure gives a fairer sense of what to expect in real life.

For context, the two lower doses tested in the same trial produced average losses of 7.5% and 8.4%. And just over half of participants (54.6%) on the top dose lost at least 10% of their body weight, with 36% losing 15% or more.

Compared with the other GLP-1 options licensed in the UK, Foundayo sits at the lower end for weight loss. This is one important reason why Foundayo is not simply a Mounjaro pill in disguise — the weight-loss results are meaningfully different:

• Foundayo (orforglipron tablet): around 11% average weight loss
• Wegovy pill (oral semaglutide): around 13.6% average weight loss
• Wegovy injection (semaglutide): around 15% average weight loss in trials
• Mounjaro injection (tirzepatide): around 20% average weight loss, and outperformed Wegovy injection directly in a head-to-head trial

No study has compared Foundayo directly against the Wegovy or Mounjaro injections, so these numbers come from separate trials in different groups of people. They're useful for a rough sense of scale, not a precise prediction of what will happen to any one person.

Does 11% weight loss actually make a difference?#

It's easy to look at those numbers and assume Mounjaro is simply "better", but that misses something important: you don't need to lose 20% of your body weight to see meaningful health benefits.

The Diabetes Prevention Program, a landmark US trial, found that people at high risk of type 2 diabetes who lost around 7% of their body weight through lifestyle changes developed diabetes 58% less often than those who didn't. A later analysis of the same data found each kilogram lost was linked to a 16% lower risk of progressing to diabetes.

The picture on heart disease is a bit murkier. The Look AHEAD trial, which followed nearly 5,000 adults with type 2 diabetes on an intensive lifestyle programme, found no overall reduction in heart attacks and strokes, and was stopped early once that became clear. But when researchers looked specifically at people who lost at least 10% of their weight in the first year, that group had a 21% lower risk of those events. That's a weaker type of evidence (it's comparing outcomes by how much weight people actually lost, not by which group they were randomly assigned to), but it's still a useful signal.

There's also solid evidence on sleep. In a long-running study of sleep-disordered breathing, a 10% weight loss was linked to a 26% reduction in the severity of obstructive sleep apnoea, where breathing repeatedly stops during sleep.

None of these studies tested Foundayo specifically, so the exact numbers won't map perfectly onto everyone taking it. But they make a fair case that the weight loss Foundayo can realistically deliver isn't a consolation prize compared to the injections. It's genuinely useful, especially for blood sugar and sleep.

How you actually take it#

Foundayo is one tablet a day, taken at any time, with or without food. There's no fasting requirement and no fixed water amount. Like most GLP-1 medications, the dose builds up gradually to reduce side effects:

• Start: 0.8mg daily
• Then: 2.5mg, 5.5mg, 9mg, 14.5mg
• Maximum: 17.2mg

Each step usually lasts at least a month before moving up, and you don't have to reach the top dose if a lower one is already working for you and you're losing weight sustainably, as long as your prescriber agrees.

Side effects are broadly similar to other GLP-1 medications: nausea, constipation, diarrhoea, vomiting, indigestion, and stomach pain are the most commonly reported, usually most noticeable when the dose increases.

Who might actually suit Foundayo#

If you're already on Mounjaro or Wegovy injections and they're working well for you, there's no obvious reason to switch. Foundayo is not an oral Mounjaro equivalent, and it doesn't outperform either injection. The best medication is generally the one that's already getting you results with side effects you can tolerate.

For people starting from scratch, it's worth thinking about your goals rather than just reaching for the strongest option available:

• If you're aiming for a larger weight loss — 25% or more — Mounjaro has the strongest trial evidence for that, and a true Mounjaro tablet (oral tirzepatide) may be worth waiting for once approved, though there is no confirmed timeline.
• If your goal is closer to a 10% loss to improve blood sugar, blood pressure, or sleep, Foundayo is a reasonable fit and comes without needles.
• If a fear of needles has been the thing stopping you from starting treatment at all, a tablet option removes that barrier entirely.

Our weight loss service talks through these options with a clinician who can look at your health history and help you weigh up what's realistic, rather than guessing based on headlines about percentages.

Using Foundayo after stopping injections#

One of the more interesting uses for Foundayo is as a maintenance tool after coming off Mounjaro or Wegovy injections. In the ATTAIN-MAINTAIN trial, 376 adults who'd already lost weight on injections were switched to either daily Foundayo or a placebo tablet for a year.

The results were fairly striking. People who'd been on Mounjaro and switched to Foundayo held onto 74.7% of their initial weight loss, compared with 49.2% on placebo. Those who'd been on Wegovy held onto 79.3%, compared with 37.6% on placebo.

Weight regain after stopping injections isn't inevitable, and how much you regain usually comes down to whether you've built sustainable habits while on treatment and whether you taper off gradually rather than stopping abruptly. Foundayo looks like it could help bridge that gap for people who want to eventually come off injectable treatment but aren't ready to stop medication support altogether.

Getting Foundayo in the UK, and why it isn't on the NHS#

MHRA approval means Foundayo can now legally be prescribed in the UK, but it will start through private prescribers — the same pattern followed by Mounjaro, the Wegovy injection, and the Wegovy pill before it. It typically takes a few weeks after approval for stock to actually reach pharmacies, so don't expect same-day availability.

Foundayo isn't funded by the NHS, and won't be until NICE completes its own separate evaluation. NICE has already started that process, with guidance expected later in 2026. That's a different question from MHRA approval, which is about whether a medicine is safe and effective enough to be prescribed at all. NICE decides whether the NHS should pay for it, and that process typically takes months even after a drug is licensed. Mounjaro and Wegovy injections went through the same two-step process before NHS specialist weight management services could offer them.

Until NICE reports, if you want to access Foundayo you'll need to go through a private prescriber. As with any newly licensed medication bought online, it's worth checking that whoever you're using is a GPhC-registered pharmacy rather than an unregulated seller, particularly given how much demand there tends to be for new GLP-1 drugs.

At Totiva, we're a GPhC-registered UK online pharmacy (registration 9012997), and we'll be adding Foundayo to our weight loss service as soon as it's available to prescribe, alongside the treatments we already offer. Currently, that includes Mounjaro injections, Wegovy injections, and the Wegovy tablet, which starts from £99 for a month's supply at the lowest 1.5mg dose. The consultation itself is free, and for GLP-1 medications like these, UK regulations require a short video call with a clinician before your first prescription, which usually takes 10 to 15 minutes.

If you're weighing up whether a tablet or injection makes more sense for you, it's worth starting that conversation now rather than waiting for Foundayo specifically. Your clinician can talk through what's actually available today and what's realistic for your situation.

Take home message#

Foundayo is not a Mounjaro pill, not oral Mounjaro, and not an oral tirzepatide — it's orforglipron, a separate drug also made by Eli Lilly. A true oral tirzepatide (oral Mounjaro / tirzepatide pill) remains in development and has not been approved anywhere. Foundayo is, however, a genuinely useful addition to the UK's weight-loss options, mostly because of how easy it is to take rather than how much weight it helps you lose. An average loss of around 11% over 72 weeks is lower than Mounjaro or the Wegovy injection, but it's still enough to meaningfully improve blood sugar, blood pressure, and sleep for a lot of people.

It isn't on sale yet, and it won't be funded by the NHS in the near future. If you're considering GLP-1 treatment now, it's worth having a proper conversation with a clinician about what's actually available today, rather than waiting on a drug that doesn't have a confirmed UK price or launch date. Totiva's pharmacist-led consultations can talk you through the current options and help you find what's realistic for your goals.